invoX Pharma Limited (“invoX”) , a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today...
/PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the...
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License...
invoX Pharma Limited (“invoX”) , a wholly owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) , focused on research and development (R&D) and business development...
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star”), operating...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of F-star Therapeutics, Inc. (NasdaqCM: FSTX)...
H.C. Wainwright analyst Patrick Trucchio maintained a Hold rating on F-star Therapeutics (FSTX – Research Report) today and set a price target of $7.00. The company's shares closed last Thursday at $6.14....
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of F-star Therapeutics, Inc. (NASDAQ: FSTX) to invoX Pharma for $7.12 per share is fair to F-star shareholders.
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...